Conclusions: In the first report to our knowledge of CDC-accredited 25(OH)D data and pregnancy outcomes from a large, clinically validated, prospective cohort study, we observed a protective association of a 25(OH)D concentration .75 nmol/L and a reduced risk of uteroplacental dysfunction as indicated by a composite outcome of SGA and pre-eclampsia. Well-designed, adequately powered randomized controlled trials are required to verify this observation. The SCOPE pregnancy cohort was registered at www.anzctr.org.au as ACTRN12607000551493.
INTRODUCTION

Because fetal and neonatal circulating 25-hydroxyvitamin D [25(OH)D]
7 concentrations are dependent on maternal status, it is important to prevent vitamin D deficiency during pregnancy (1) . However, vitamin D deficiency has been reported extensively in gravidae from ethnic minority groups (2) (3) (4) (5) , and low 25(OH)D concentrations are also common in white women during pregnancy (5) (6) (7) (8) (9) . This deficiency has been associated with adverse perinatal outcomes including pre-eclampsia (10), gestational diabetes (11) , and low birth weight (12) , although the data have been inconsistent. The
Institute of Medicine defines a serum 25(OH)D concentration ,30 nmol/L as the concentration at which there is increased risk of vitamin D deficiency, 40 nmol/L as the adequacy threshold, and $50 nmol/L as vitamin D sufficiency (13) on the basis of skeletal health outcomes. Although the total amount of most nutrients in circulation increases during pregnancy, hemodilution may cause concentrations to decrease from w10 wk of gestation (14) . The appropriateness of comparing 25(OH)D concentrations in pregnant women with thresholds established in nonpregnant adults is questionable (1) , and it is possible that pregnancy-specific cutoffs of 25(OH)D concentration are required (15, 16) .
Vitamin D metabolites, such as 3-epi-25-hydroxyvitamin D 3 [3-epi-25 3 , showing that C-3 epimerization may be a common metabolic pathway for vitamin D 3 metabolites in selected cells independent of cytochrome P-450 enzymes (17) (18) (19) . Despite having shown the in vitro biological activity, the clinical significance of 3-epi-25(OH)D 3 is still unknown, and 3-epi-25(OH)D 3 is not included in the calculation of total 25(OH)D (20, 21) . However, 3-epi-25(OH)D 3 is present in most individuals at low circulating concentrations and in a relatively higher proportion to total 25(OH)D in infants (22) (23) (24) . On the basis of a recent systematic review, Bailey et al. (21) recommended that more clinical studies are required that describe the relation between serum 25(OH)D 3 and 3-epi-25(OH)D 3 . We recently reported determinants of 3-epi-25(OH)D 3 in a large, representative sample of Irish adults (25) . Differences in the distributions and concentrations of 3-epi-25(OH)D 3 from a previous report in a smaller sample (26) were likely due to differences in the analytic methods and characterization of participants. Currently, there are limited data on 3-epi-25(OH)D 3 in small samples of pregnant women (27, 28) .
Similarly, data on circulating 25(OH)D 2 during pregnancy are scarce. Although the metabolisms of vitamin D 2 and vitamin D 3 in the human body are similar (29) , their equivalency has been debated (30) . Two systematic reviews (31, 32) reported that vitamin D 3 is more effective in raising serum 25(OH)D concentrations than is vitamin D 2 ; this finding is potentially important in populations that may be vulnerable to vitamin D deficiency such as pregnant women. Thus, the aims of the current study were to describe the concentrations of 25(OH)D 3 , 3-epi-25(OH)D 3 , and 25(OH)D 2 in a large, well-phenotyped, prospective pregnancy cohort who were resident at 528N and to investigate associations between vitamin D status and preeclampsia and small-for-gestational-age (SGA) birth, which are indicative of uteroplacental dysfunction.
METHODS
Study design
A total of 1768 participants who attended for antenatal care at Cork University Maternity Hospital, Cork, Ireland (528N), were recruited to SCOPE (Screening for Pregnancy Endpoints) Ireland study (www.anzctr.org.au; ACTRN12607000551493) before 15 wk of gestation between March 2008 and January 2011 (the participant flowchart is shown in Supplemental Figure 1 ). Complete details of the clinical study and data collection have been provided elsewhere (33, 34) . Briefly, the main inclusion criteria were a low-risk pregnancy, a singleton pregnancy ,15 wk of gestation, and no previous pregnancy .20 wk of gestation. Specific exclusion criteria were as follows: predetermined high risk of pre-eclampsia; an SGA baby; or spontaneous preterm birth because of underlying medical conditions including chronic hypertension requiring antihypertensive drugs, diabetes, renal disease, systemic lupus erythematosus, antiphospholipid syndrome, sickle cell disease, HIV, a previous cervical knife cone biopsy, $3 terminations of a pregnancy, $3 miscarriages, or current ruptured membranes; known major fetal anomaly or abnormal karyotype; or an intervention that could modify the outcome of pregnancy (such as aspirin use or cervical cerclage).
All women provided written informed consent and had their first SCOPE visit at 15 wk of gestation (range: 14-16 wk of gestation). Research midwives interviewed participants and collected information on socioeconomic status, occupation, educational attainment, marital or relationship status, and a complete medical history. Data on nutritional supplement use, including brand names, alcohol consumption, smoking history, and recreational drug use, were recorded for the period before conception, during the first trimester, and at the time of the 15-wk visit. Habitual occupational and recreational physical activity was investigated with the use of a standard questionnaire that recorded the frequency and time spent in light and moderate or vigorous activities over a typical month. Vigorous exercise was defined as daily exercise leading to heavy breathing or being out of breath (35) . Maternal anthropometric measurements [height and weight for the calculation of BMI (in kg/m
2 )] were carried out, blood pressure (BP) (2 consecutive measurements taken with the use of a mercury or aneroid sphygmomanometer) was measured, proteinuria was assessed with the use of a semiquantitative, automated dip-stick reading, and a nonfasting blood sample was obtained from each participant. Blood was processed within 3 h to serum and stored at 2808C for future analysis.
Clinical characterization of pregnancy outcomes
Participants were followed prospectively, and pregnancyoutcome data and neonatal measurements were classified according to predefined protocols. Pre-eclampsia was defined as having systolic BP $140 mm Hg or diastolic BP $90 mm Hg on $2 occasions 4 h apart after 20 wk of gestation but before the onset of labor or postpartum with either proteinuria (24-h urinary protein $300 mg or a spot urine protein:creatinine ratio $30 mg/mmol creatinine or urine dipstick protein $2) or any multisystem complication of pre-eclampsia (33) . Secondary diagnoses of pre-eclampsia were term pre-eclampsia (gestation at delivery $37 wk), preterm pre-eclampsia (gestation at delivery ,37 wk), and early-onset pre-eclampsia (gestation at delivery ,34 wk). SGA was defined as a birth weight ,10th of the customized percentile adjusted for maternal height, booking weight, ethnicity, delivery gestation, and infant sex. The combined prevalence of pre-eclampsia and SGA was indicative of uteroplacental dysfunction. Research midwives entered all data into a certified, secure, Internet-deployed, custom database (MedSciNet AB). Data were extensively monitored throughout the study.
Analytic methods
Circulating 25(OH)D 3 , 3-epi-25(OH)D 3 , and 25(OH)D 2 concentrations were measured at the Cork Centre for Vitamin D and Nutrition Research laboratory with the use of a liquid chromatography-tandem mass spectrometry (LC-MS/MS) method, which has been fully described earlier (25, 34, 35) . The instrument used was a Waters Acquity UPLC system coupled to an Acquity Triple Quadrupole TQD mass-spectrometer detector (Waters). Concentrations of 25(OH)D 3 and 25(OH)D 2 were quantified individually, and their values were summed to generate total 25(OH)D. Chromatographic separation and quantitation of 3-epi-25(OH)D 3 were also achieved. Four amounts of serum-based National Institute of Standards and Technologycertified quality-assurance material (standard reference material 972) were used for method validation, whereas quality-control materials that were assayed in parallel to all samples were purchased from Chromsystems. National Institute of Standards and Technology calibrators were used throughout the analysis (standard reference material 2972). The interassay CV was ,5% for all metabolites, and the intra-assay CV was ,6%. (36); data describing the excellent performance of our vitamin D analytic method in this project have been provided previously (25, 37, 38) .
Statistical analysis
The statistical analysis was conducted with the use of PASW Statistics version 20.0 software (SPSS, IBM) and STATA 13.0 (StataCorp LP) software. Descriptive statistics (mean 6 SD; median and IQR; and frequency and percentage) were determined for all variables. Seasonal differences were tested with the use of the Mann-Whitney U test for independent samples. Cutoffs for serum 25(OH)D that were proposed by the Institute of Medicine (13) and in the vitamin D literature were used to describe the prevalence of 25(OH)D below various thresholds. Multiple linear regression was used to explore the predictors for concentrations of 25(OH)D and 3-epi-25(OH)D 3 at 15 wk of gestation. Determinants of total 25(OH)D were explored in unadjusted models, and determinants that had a P value #0.1 were included in the multivariate model. The residuals of the multiple linear regression model were slightly deviated from the normal distribution; therefore, square-root transformation for the 25(OH)D variable was used, and the residuals were approximately normally distributed when the regression model was repeated. However, because the regression models on the original scale and the square-root transformation scale identified the same factors as significantly associated with 25(OH)D, we report the results from the linear regression model without transformation. The robust option in the STATA program was used with the linear regression models to ensure robust 95% CIs. All tests were 2-sided at the 5% statistical significance level. To assess the association between 25(OH)D 3 and 3-epi-25(OH)D 3 , we fitted a fractional polynomial linear regression model with 3-epi-25(OH)D 3 as the outcome and with 25(OH)D 3 as the predictor. We performed crude and adjusted logistic regression models to examine the association between total 25(OH)D and 25(OH)D 3 and risks of pre-eclampsia and SGA birth and the composite outcome of pre-eclampsia and SGA as indicative of uteroplacental dysfunction. The models were adjusted for data collected at the 15-wk visit, including vitamin supplementation, the season of the blood sample, the number of summer days during pregnancy, recreational walking, job status, socioeconomic index, maternal age, BMI, smoking, alcohol use, education, ethnic origin, and marital status.
RESULTS
Sample description
Characteristics of the cohort of 1768 low-risk primiparous women at 15 wk of gestation are presented in Table 1 . The mean 6 SD maternal age was 30.5 6 4.5 y, mean 6 SD BMI was 24.9 6 4.2, mean systolic BP was 105 mm Hg (10), and mean diastolic BP was 66 mm Hg (7). The cohort was primarily white skinned, and the 41 women of non-European origin were Chinese, South Asian, and African. Most women were married or in a stable relationship, and w50% of women had a tertiary education. Of the 40% of women who were taking vitamin D-containing supplements, 82% consumed 5 mg/d. Doses ranged from 2.5 to 10 mg/d, and almost all products (97%) contained vitamin D 3 . 
Vitamin D status
Pregnancy outcome
The prevalence of pre-eclampsia was 3.8% (70% were term pre-eclampsia cases), and 10.7% of infants were SGA births with a combined prevalence of 13.6%. The association of total 25(OH)D with pre-eclampsia, SGA, and pre-eclampsia plus SGA as a composite indicator of uteroplacental dysfunction is presented in Table 5 . Table 4 as well as for additional sociodemographic characteristics that are known to influence the pregnancy outcome. There was no adverse effect of high 25(OH)D, although the number of women with concentrations .125 nmol/L was small (n = 8). 3 were all higher in the summer (P , 0.001), and 25(OH)D 2 was higher in the winter (P , 0.001). 
DISCUSSION
To our knowledge, this is the first report of serum concentrations of 25(OH)D 3 analyzed with the use of a CDC-accredited LC-MS/ MS method in a large prospective pregnancy cohort with clinically validated pregnancy outcomes. We observed an independent protective association between serum 25(OH)D concentrations .75 nmol/L and reduced risk of uteroplacental dysfunction as indicated by a composite pre-eclampsia plus SGA outcome. This is one of the largest population studies, and the largest study in pregnant women, to describe the distribution of 3-epi-25(OH)D 3 , which was detectable in every participant with a serum 25(OH)D concentration .15 nmol/L and was almost entirely attributable to circulating 25(OH)D 3 . Another novel aspect of this study was the description of circulating 25(OH)D 2 , which was present in almost all women, although vitamin D 2 was consumed in supplement form by a small minority.
Our estimates of 17% and 44% of women with 25(OH)D concentrations ,30 and ,50 nmol/L, respectively, were higher than those presented in most reports of Caucasian women at a similar latitude including in the Netherlands (5), Canada (6), the United Kingdom (7), and Boston (8) . In Scotland (578N), 21.5% of concentrations were ,25 nmol/L at 19 wk of gestation (39) (44), which was also in agreement with our data and other data in nonpregnant adults (45) .
Women in Ireland are not currently recommended by the authoritative agency to take vitamin D supplements during pregnancy. However, like other results (4, 5, 46, 47) , our data emphasize that supplements are effective only in individuals who choose to take them. People who are the most vulnerable in the population (e.g., dark-skinned individuals who do not take a supplement) are at highest risk of deficiency. Although the subsample of dark-skinned women in this cohort was small, the very high prevalence of vitamin D deficiency in women of non-European origin who did not use supplements (70%) or who had 25(OH)D concentrations ,30 nmol/L highlighted the significance of ethnicity as a risk factor during pregnancy. There is an urgent requirement for food-based strategies to increase the mean population intake to $10 mg/d and to prevent 25(OH)D concentrations falling to ,30 nmol/L, which would benefit all of society, including women during pregnancy.
Our study observed a protective association, which was equivalent to a 36% reduction, of a composite outcome of pre-eclampsia plus SGA that was indicative of uteroplacental dysfunction in VITAMIN D AND PREGNANCY OUTCOME women with 25(OH)D concentrations .75 nmol/L. Almost 1 in 20 pregnancies in the European Union are complicated by preeclampsia, which is the most prevalent cause of maternal mortality in Europe, accounting for 17-24% of all maternal deaths, and is associated globally with w80,000 maternal and .500,000 infant deaths annually (48) . In the longer term, pre-eclampsia is also associated with increased risk of cardiometabolic diseases later in a woman's life (49) , and because gestational hypertension, with or without pre-eclampsia, creates a predisposal to growth restriction and an SGA birth, the prevention of pre-eclampsia is of paramount importance for healthy prenatal and postnatal growth. All values are ORs (95% CIs). Logistic regression was used to examine the association between total 25(OH)D and risk of pre-eclampsia and SGA birth and the composite outcome of pre-eclampsia and SGA as indicative of uteroplacental dysfunction. Models were adjusted for data collected at the 15-wk visit including supplementation, the season of sampling, the number of summer days during pregnancy, recreational walking, and job status. Additional adjustment for socioeconomic index, maternal age, BMI, smoking, alcohol use, education, ethnic origin, and marital status did not change the results materially. SCOPE, Screening for Pregnancy Endpoints; SGA, small for gestational age; 25(OH)D, 25-hydroxyvitamin D. of low quality, the absence of the reporting of adverse effects, and high risk of bias in most studies. Two systematic reviews of 25(OH)D and pregnancy outcomes in observational studies (51, 52) highlighted the limitations imposed by high levels of heterogeneity and decided that the evidence was insufficient to draw firm conclusions. Clearly, many gaps remain in the investigation of vitamin D and perinatal outcomes.
Aghajafari et al. (51) were persuaded that, because of the mechanistic underpinning and biological plausibility of the associations between vitamin D and metabolic abnormalities, including hypertension, plus the relative consistency in the observational data and the likelihood that low 25(OH)D preceded the adverse outcome (thereby reducing the likelihood of reverse causation), intervention studies with defined outcomes were warranted. However the authors cautioned that these defined outcomes would only be valuable if comprehensive data were collected on nutrition, clinical characteristics, family histories, and relevant lifestyle factors such as sun exposure. Similarly, Thorne-Lyman and Fawzi (52) concluded that the evidence was insufficient to draw firm conclusions other than that intervention studies with defined outcomes in pregnancy were warranted in populations with a high prevalence of deficiency and at doses that were sufficient to achieve 25(OH)D targets.
At this point, we know that maternal vitamin D deficiency is completely preventable. The question of whether there is a detectable therapeutic window for an additional benefit if every woman who participates in an intervention study is prevented from becoming deficient [at a minimum of 30 nmol 25(OH)D/L] is a critical ethical and methodologic issue in terms of designing and implementing placebo-controlled vitamin D-intervention studies in pregnant women. Furthermore, there are many unanswered questions, and few investigators have systematically addressed the issue of habitual calcium intake in conjunction with low vitamin D status as evidence by elevated parathyroid hormone concomitant with low 25(OH)D (53) .
Our study makes a significant contribution to the evidence base because of the quality of the study design and implementation, the clinical phenotyping, biobanking protocols, and accredited analytic data. However, we could not rule out the possibility of reverse causation. The detailed description of the clinical modifiers for 25(OH)D showed that, in addition to the season and ethnicity, lifestyle variables, such as current smoking, and recreational activity, such as regular walking, are potentially important. Because these clinical and lifestyle factors are also implicated in the risk profile that predisposes individuals to adverse perinatal outcomes (33) , it is important that the factors are acknowledged as contributing both to low serum 25(OH)D concentrations and increased risk of disease. In our view, adjustment for these factors in the statistical analysis would have been unlikely to fully account for them in the pathologic process.
From an analytic point of view, these are the largest and most comprehensive data on 3-epi-25(OH)D 3 in pregnancy to our knowledge. Variations in 3-epi-25(OH)D 3 tracked 25(OH)D 3 concentrations on a month-by-month basis. The question of whether 3-epi-25(OH)D 3 elicits independent biological effects can only be further investigated when the purified compound can be manufactured at a standard and quantity that are suitable for human consumption in clinical studies. We also detected 25(OH)D 2 in almost 100% of the cohort and showed an inverse association between 25(OH)D 2 and 25(OH)D 3 in the subgroup of women who consumed vitamin D 2 supplements. With regard to the source of 25(OH)D 2 in the diet of nonusers of supplements, we assume it arose from voluntary fortification and endogenous sources, such as mushrooms, similar to what was shown in a previous report in Irish adults (38) .
In conclusion, we report a protective association of a 25(OH)D concentration .75 nmol/L and a reduced risk of uteroplacental dysfunction as indicated by a composite outcome of SGA and pre-eclampsia. Well-powered vitamin D intervention studies in pregnancy are warranted; however, there are significant ethical and design considerations.
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